UNH · Q2 2025 Earnings
BearishUnitedHealth Group
Reported July 29, 2025
30-second summary
Revenue grew 12.9% YoY to $111.6B but the medical care ratio blew out to 89.4% and operating margin compressed to 4.6%, driving adjusted EPS of $4.08 and a reset FY2025 outlook of "at least $16.00" adjusted EPS on $445.5–448.0B revenue. New CEO-led tone is unusually candid — "we've made pricing and operational mistakes" — with independent expert reviews of risk coding, care management, and pharmacy services now annualized. The investable question is whether 2026 is the trough; management says yes, but the path requires absorbing a $4B remaining V28 headwind in 2026 with management targeting roughly 50% mitigation, Medicare Advantage margins reaching 2.5–3.0%, and Medicaid going further negative before recovering.
Headline numbers
EPS
Q2 FY2025
$4.08
Revenue
Q2 FY2025
$111.60B
+12.9% YoY
Operating margin
Q2 FY2025
4.6%
Key financials
Q2 FY2025| Metric | Q2 FY2025 | YoY |
|---|---|---|
| Revenue | $111.60B | +12.9% |
| EPS | $4.08 | — |
| Operating margin | 4.6% | — |
Guidance
Prior quarter data unavailable — comparison not possible.
Segment KPIs
Q2 FY2025| Segment | Q2 FY2025 | YoY |
|---|---|---|
| UnitedHealthcare | $86.1B | +16.5% |
| Optum | $67.2B | +6.9% |
| UnitedHealthcare - Employer & Individual | $19.8B | +2.8% |
| UnitedHealthcare - Medicare & Retirement | $42.6B | +22.0% |
| UnitedHealthcare - Community & State | $23.7B | +20.2% |
| Optum Health | $25.2B | -7.1% |
| Optum Insight | $4.8B | +6.3% |
| Optum Rx | $38.5B | +18.7% |
Other KPIs
Q2 FY2025| Segment | Q2 FY2025 |
|---|---|
| Medical Care Ratio | 89.4% |
| Operating Cost Ratio | 12.3% |
| UnitedHealthcare People Served | 50.0 million |
| Optum Health Value-Based Care Patients | 5.0 million |
| Optum Insight Contract Revenue Backlog | $32.1 billion |
| Optum Rx Adjusted Scripts | 414 million |
| Days Claims Payable | 44.5 |
| Return on Equity (annualized YTD) | 20.6% |
Management tone
This is a defensive, introspective call that breaks sharply from UnitedHealth's historical posture. Five concurrent shifts:
From operational excellence as differentiator to explicit admission of failure. UnitedHealth has spent a decade selling capital markets on disciplined underwriting and integrated execution. New CEO framing — "we've made pricing and operational mistakes as well as others" — is rare candor for any large-cap, let alone for this management team. The signal is that the issues driving the guide-down are not purely environmental; they are internal, and remediating them is a management project rather than a wait-for-the-cycle project.
From confidence in internal processes to mandated external review. "Our critical processes, including risk status, care management, pharmaceutical services, and others, are being reviewed by independent experts, and they will be reviewed every year and reported on." Annualized external audit of risk coding is not a routine governance enhancement — it is a response to specific regulatory and public scrutiny on managed care practices, and it constrains the company's degrees of freedom on coding intensity, historically a meaningful EPS lever.
From regulatory compliance as baseline to proactive engagement. "We have embarked on a real cultural shift in our relationship with regulators and all external stakeholders. We intend to be proactively engaged, constructive, and responsive." Reads as preparation for a multi-year environment where Medicare Advantage rate-setting, Medicaid actuarial reviews, and PBM scrutiny are all less favorable than the 2015–2023 window.
From business-as-usual portfolio management to "reconsidered and redirected." "Some require a fundamental reorientation, others require building and nurturing, and others must be reconsidered and redirected to original purpose" telegraphs that portfolio-wide performance problems exist, not isolated ones. Patrick Conway's prepared remarks confirmed the company is "pausing previously planned portfolio actions to prioritize growth and innovation" — meaning previously contemplated divestitures are off the table and the businesses must be fixed in place.
From earnings-growth posture to trough-and-rebuild posture. Stephen Hemsley said the framework for the long-term growth outlook "remains very much intact" and that he expects the company to pace back steadily to low double-digit ranges, but explicitly acknowledged the near-term growth rates do not reflect the enterprise's potential. The work for investors becomes: triangulate the 2026 floor and assess whether the 2.5–3.0% MA margin and 1% value-based care margin targets are credible.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
AJ Rice · UBS
How does UnitedHealthcare's Medicare Advantage repricing for 2026 flow through to OptumHealth capitation rates? Are outside payer partners also repricing for more reasonable margins in 2026?
Patrick Conway confirmed that UHC pricing adjustments flow into OptumHealth's capitation rates as a tailwind. Payer partners are working closely with OptumHealth on benefit reductions and tighter bidirectional dialogue. These measures are expected to mitigate approximately 50% of the remaining $4 billion V28 headwind in 2026, with the other 50% coming from operating cost reductions and patient cohort engagement. OptumHealth expects to maintain 1% margins in 2026 before advancing in 2027.
Justin Lake · Wolf Research
What is the run-rate earnings for 2H 2025 and what are the moving parts driving EPS growth into 2026, specifically regarding Medicare Advantage margins?
Management confirmed the analyst's math of approximately $13/share run-rate earnings (roughly $5-6 per share for 2H after adjusting for discrete items). Bobby Valentine noted Medicare Advantage margins are expected at 2.0-2.5% for 2025 and will expand to 2.5-3.0% in 2026 through benefit cuts, plan reductions, and higher trend pricing assumptions. The 80% of premiums repricing on January 1 creates significant leverage into 2026.
Stephen Baxter · Wells Fargo
What were the previous value-based care target margins to compare against the new 5% target? What margin drivers beyond 2026 will help OptumHealth achieve the 5% value-based care margin, apart from Medicare Advantage repricing?
Management clarified that the 5% long-term target for value-based care reflects a more circumspect view on timing and investment needs. Patrick Conway detailed cohort performance: negative margins for years 1-2 (currently 40% of membership), 2% margins for years 3-4, and 8%+ margins for year 5+. By shifting to 25-30% year 1-2 cohorts and 40%+ year 5+ cohorts, blended 5-6% margins are achievable. Fee-for-service services businesses (10% margins) and care delivery improvements will also contribute.
Ann Himes · Mizuho Securities
What is the Medicaid margin target and expected margin for 2026? What is the expected premium increase rate for 2026 across the portfolio (noted as 80% repricing)?
Tim Nolan clarified Medicaid target margins: 2% for core non-dual, with 3-5% historically in community and state blended. 2025 Medicaid is expected at breakeven for non-dual; 2026 is expected to show negative margins of -1% to -1.7% due to lag in state rate updates and elevated behavioral health trends. Commercial premium increases are expected at double-digit rates for 2026; Medicaid combined premium increases are expected comparable to 2025 at ~6%; Medicare tracks CMS adjustments.
Josh Raskin · Nephron Research
What is the updated long-term EPS growth rate guidance, and are there updated target margins for UnitedHealthcare and other Optum segments?
John Rex indicated the company does not expect to update its long-term EPS growth framework (historically 13-16%) in the near term, as current guidance does not reflect the enterprise's full potential. Management stated the framework for long-term growth remains intact: organic growth, productivity compounding, capital compounding (buybacks), and business model evolution. No changes to UnitedHealthcare target margin ranges were announced. OptumHealth target updated to 6-8% (down from prior unstated guidance), with value-based care at 5%.
What to watch into next quarter
MCR trajectory vs. the 89.25% +/- 25bps FY guide. Q2 came in at 89.4% — already at the top of the guided band. Q3 above 89.5% would imply FY likely exceeds the high end, putting the "at least $16.00" adjusted EPS floor at risk.
OptumHealth revenue stabilization. Down 6.8% YoY this quarter. Watch whether Q3 narrows to a mid-single-digit decline or worsens — a continued widening would undermine the 1% 2026 value-based care margin target before repricing leverage arrives.
Operating cost ratio glide path. Q2 at 12.3% is running 45bps below the FY 12.75% midpoint. Management can flex this to defend EPS; watch for cost cuts disclosed alongside the next print as evidence of how much room they have.
Specifics on 2026 MA bid filings and benefit reductions. The 2.5–3.0% MA margin recovery relies on benefit cuts and plan exits that get filed mid-year. Disclosure of plan footprint changes or membership guidance for 2026 before year-end would materially de-risk the rebuild thesis.
Independent expert review findings. Management committed to annual external review and public reporting on risk coding, care management, and pharmacy services. The first such report — and any restated practices it prompts — is a binary event for the coding-intensity earnings lever.
Sources
- UnitedHealth Group Q2 2025 Press Release / Form 8-K Exhibit 99.1 — https://www.sec.gov/Archives/edgar/data/731766/000073176625000228/a2025q2exhibit991.htm
- UnitedHealth Group Q2 2025 earnings call — prepared remarks (Hemsley, Noel, Conway, Rex) and Q&A (AJ Rice/UBS, Justin Lake/Wolf Research, Josh Raskin/Nephron Research, Kevin Fischbeck/Bank of America), July 29, 2025
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.